Front. Pharmacol. Frontiers in Pharmacology Front. Pharmacol. 1663-9812 Frontiers Media S.A. 1495855 10.3389/fphar.2024.1495855 Pharmacology Correction Corrigendum: Inhibitory effects of calcium channel blockers nisoldipine and nimodipine on ivacaftor metabolism and their underlying mechanism Xia et al. 10.3389/fphar.2024.1495855 Xia Hailun Xu Xinhao Chen Jie Wu Hualu Shen Yuxin Chen Xiaohai Xu Ren-ai * Wu Wenzhi * First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China

Edited and reviewed by: Junmei Wang, University of Pittsburgh, United States

 *Correspondence: Wenzhi Wu, wwzljy@163.com; Ren-ai Xu, xra@wmu.edu.cn 27 09 2024 2024 15 1495855 13 09 2024 23 09 2024 Copyright © 2024 Xia, Xu, Chen, Wu, Shen, Chen, Xu and Wu. 2024 Xia, Xu, Chen, Wu, Shen, Chen, Xu and Wu

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

 A Corrigendum on Inhibitory effects of calcium channel blockers nisoldipine and nimodipine on ivacaftor metabolism and their underlying mechanism by Xia H, Xu X, Chen J, Wu H, Shen Y, Chen X, Xu R-a and Wu W (2024). Front. Pharmacol. 15:1403649. doi: 10.3389/fphar.2024.1403649 cystic fibrosis ivacaftor nisoldipine nimodipine drug-drug interaction pharmacokinetics section-at-acceptance Drug Metabolism and Transport

In the published article, there was an error in Figure 7 as published. During the mapping process, the wrong unit of concentration value was used. Previous mapping used mg/mL as the unit of concentration for the X-value, which is inconsistent with the unit used for the figure, and is now converted to μM. The resulting Ki-values change from 0.17 and 0.30 to 3.26 and 5.87, respectively. The corrected Figure 7 and its caption appear below.

Lineweaver-burk plot, secondary diagram of Ki inhibiting ivacaftor metabolism at different concentrations of nimodipine in RLM (A) and in HLM (B).

In the published article, there was an error in Table 2 as published. During the mapping process, the wrong unit of concentration value was used for Nimodipine. Previous mapping used mg/mL as the unit of concentration for the X-value, which is inconsistent with the unit used in the table, and is now converted to μM. The resulting Ki-values change from 0.17 and 0.30 to 3.26 and 5.87, respectively. The corrected Table 2 and its caption appear below.

The IC50 values and inhibitory effects of nisoldipine and nimodipine on ivacaftor metabolism in RLM and HLM.

Inhibitors IC50 values (μM) Inhibition type Ki (μM) αKi (μM) α
Nisoldipine RLM 6.55 non-competitive inhibition and competitive inhibition 3.35 8.48 2.53
HLM 9.10 non-competitive inhibition and competitive inhibition 3.92 35.40 9.03
Nimodipine RLM 4.57 competitive inhibition 3.26
HLM 7.15 competitive inhibition 5.87

In the published article, there was an error. During the mapping process, the wrong unit of concentration value was used. Previous mapping used mg/mL as the unit of concentration for the X-value and is now converted to μM. The resulting Ki-values change from 0.17 and 0.30 to 3.26 and 5.87, respectively.

A correction has been made to 3 Results, 3.3 Nisoldipine and nimodipine inhibited ivacaftor metabolism in RLM and in HLM through different inhibitory mechanisms. This sentence previously stated:

“The Ki values were 0.17 and 0.30, respectively (Table 2).”

The corrected sentence appears below:

“The Ki values were 3.26 and 5.87, respectively (Table 2).”

The authors apologize for these errors and state that these do not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.